<DOC>
	<DOCNO>NCT01661738</DOCNO>
	<brief_summary>The clinical trial design evaluate safety immunogenicity Group ACYW135 Meningococcal Polysaccharide Vaccine Hualan administer subject 2 year age old .</brief_summary>
	<brief_title>Clinical Trial Group ACYW135 Meningococcal Polysaccharide Vaccine 002</brief_title>
	<detailed_description>Complying requirement approval letter clinical trial issue SFDA ( Approval Letter No . : 2006L01017 ) , Hualan conduct phase II clinical trial Group ACYW135 Meningococcal Polysaccharide Vaccine evaluate safety immunogenicity experimental vaccine . The safety end point presence systemic , local adverse reaction . Evaluation indicator immunogenicity bacteriocin level group A , C , Y W135 respectively serum whole vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy permanent residence 2 year age old , subject ( guardian ) able understand sign inform consent ; Healthy male female oral history , physical examination clinical judgment complies vaccination product ; Be able comply requirement clinical trial protocol immunogenicity examination ; Have history vaccination within past 3 month vaccination product within last 2 week ; Axillary temperature ≤37.0℃ . Any acute disease , : tumor , autoimmunity disease , progressive atherosclerotic disease diabetes complication , chronic obstructive pulmonary disease need oxygen uptake , acute progressive hepatopathy nephropathy , congestive heartfailure , etc . ; Allergic vaccine drug ( history allergy vaccine past ) ; History neurologic symptom sign ; Known suspect ( high risk ) impair abnormal immune function , e.g . : receive immunosuppressant immunopotentiator therapy , take immunoglobulin blood product plasma extract ( except gastrointestinal tract ) within past 3 month , HIV infection related disease , etc . ; History meningitis infection vaccination meningococcal vaccine within past 3 month ; History receive vaccine immunoglobulin injection research drug ; Any acute disease need application antibiotic antivirus treatment whole body within past 1 week ; History fever within past 3 day ( axillary temperature ≥38.0℃ ) ; Participating another clinical trial ; History allergy , eclampsia , epilepsy , encephalopathy mental disease family disease ; Thrombopenia coagulopathy may cause contraindication intramuscular injection ; Acute chronic disease ( Down syndrome , diabetes , sickle cell anemia neurologic disease , GuillainBarre Syndrome ) ; Known suspected disease , include : respiratory system disease , acute infection active stage chronic disease , SBAV infection child mother , cardiovascular disease , acute hypertension , cancer treatment , skin disease , etc . ; Pregnancy Any condition , judgment investigator , may affect trial assessment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Group ACYW135 Meninigococcal Polysaccharide Vaccine</keyword>
</DOC>